![Brendan O’Leary](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brendan O’Leary
Directeur des opérations chez Xalud Therapeutics, Inc.
Profil
Brendan O’Leary currently works at Xalud Therapeutics, Inc., as Chief Operating Officer from 2021.
Postes actifs de Brendan O’Leary
Sociétés | Poste | Début |
---|---|---|
Xalud Therapeutics, Inc.
![]() Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | Directeur des opérations | 11/05/2021 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Xalud Therapeutics, Inc.
![]() Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | Health Technology |